COMP <GO>
ACTU vs TXMD // EV/EBITDA & P/E VALUATION
Actuate Therapeutics Inc. (NASDAQ) VS. TherapeuticsMD Inc. (NASDAQ) • 15-METRIC TALLY: ACTU 1
— TXMD 3
■ METRIC PARITY
LAST: $0.37 (-3.21%) • MKT CAP: $20.4M
valuation
—
LAST: $1.83 (+2.24%) • MKT CAP: $21.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACTU VS. TXMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACTU | TXMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -12.90% | -22.10 | TXMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ACTU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.1 | 33.3 | -1.23 | TXMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $20.4M | $21.2M | -$776.3K | TXMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACTU REV | TXMD REV | ACTU GROSS % | TXMD GROSS % | ACTU FCF | TXMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$19.2M | — |
| FY 2024 | $0 | $1.8M | — | — | -$21.8M | — |
| FY 2023 | $0 | $1.3M | — | — | -$21.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACTU // BETA —
TXMD // BETA —